Literature DB >> 19011662

Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.

F Bernard1, P Bordigoni, M-C Simeoni, V Barlogis, A Contet, A Loundou, I Thuret, B Leheup, H Chambost, B Play, P Auquier, G Michel.   

Abstract

We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal). Heights were measured at three key periods, that is, transplantation, before adolescence, and FH, and compared using height standard deviation score (SDS) and cumulative change in SDS. The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation. Overall mean height SDS was near normal at transplantation and before adolescence (0.2+/-0.1 and -0.2+/-0.1, respectively), but decreased to -1.6+/-0.1 at FH. There were significant differences between the TBI and BU groups when comparing FH SDS (-1.8+/-0.2 vs -0.8+/-0.2, P=0.001), mean change in height SDS from transplantation to FH (-2+/-0.1 vs -1.1+/-0.2, P=0.002) and mean change in height SDS during adolescence (-1.6+/-0.1 vs -0.7+/-0.2, P=0.003). We conclude that preparations involving BU, although less toxic than TBI-containing regimens, also have adverse effects on growth, predominantly during adolescence.

Entities:  

Mesh:

Year:  2008        PMID: 19011662     DOI: 10.1038/bmt.2008.370

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

Authors:  Barbara Spitzer; Ann A Jakubowski; Esperanza B Papadopoulos; Kirsten Fuller; Patrick D Hilden; James W Young; Juliet N Barker; Guenther Koehne; Miguel-Angel Perales; Katharine C Hsu; Marcel R van den Brink; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Hugo Castro-Malaspina; Richard J O'Reilly; Farid Boulad
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-12       Impact factor: 5.742

2.  Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort).

Authors:  Julie Berbis; Gérard Michel; André Baruchel; Yves Bertrand; Pascal Chastagner; François Demeocq; Justyna Kanold; Guy Leverger; Dominique Plantaz; Marilyne Poirée; Jean-Louis Stephan; Pascal Auquier; Audrey Contet; Jean-Hugues Dalle; Stéphane Ducassou; Virginie Gandemer; Patrick Lutz; Nicolas Sirvent; Marie-Dominique Tabone; Sandrine Thouvenin-Doulet
Journal:  Int J Epidemiol       Date:  2014-03-17       Impact factor: 7.196

3.  Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H).

Authors:  Chris J Gardner; Nicola Robinson; Tim Meadows; Robert Wynn; Andrew Will; Jean Mercer; Heather J Church; Karen Tylee; J Edmond Wraith; Peter E Clayton
Journal:  J Inherit Metab Dis       Date:  2011-01-21       Impact factor: 4.982

4.  Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

Authors:  F Bernard; P Auquier; I Herrmann; A Contet; M Poiree; F Demeocq; D Plantaz; C Galambrun; V Barlogis; J Berbis; F Garnier; N Sirvent; J Kanold; P Chastagner; H Chambost; G Michel
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

5.  Growth impairment after TBI of leukemia survivors children: a model- based investigation.

Authors:  Chiara Galletto; Antonio Gliozzi; Daniele Nucera; Nicoletta Bertorello; Eleonora Biasin; Andrea Corrias; Patrizia Chiabotto; Franca Fagioli; Caterina Guiot
Journal:  Theor Biol Med Model       Date:  2014-10-13       Impact factor: 2.432

6.  Impairments that influence physical function among survivors of childhood cancer.

Authors:  Carmen L Wilson; Prasad L Gawade; Kirsten K Ness
Journal:  Children (Basel)       Date:  2015

7.  Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience.

Authors:  Ilhem Rahal; Claire Galambrun; Yves Bertrand; Nathalie Garnier; Catherine Paillard; Pierre Frange; Corinne Pondarré; Jean Hugues Dalle; Regis Peffault de Latour; Mauricette Michallet; Dominique Steschenko; Despina Moshous; Patrick Lutz; Jean Louis Stephan; Pierre Simon Rohrlich; Ibrahim Yakoub-Agha; Françoise Bernaudin; Christophe Piguet; Nathalie Aladjidi; Catherine Badens; Claire Berger; Gérard Socié; Cécile Dumesnil; Marie Pierre Castex; Marilyne Poirée; Anne Lambilliotte; Caroline Thomas; Pauline Simon; Pascal Auquier; Gérard Michel; Anderson Loundou; Imane Agouti; Isabelle Thuret
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

Review 8.  Two Different Transplant Preconditioning Regimens Combined with Irradiation and Chemotherapy in the Treatment of Childhood Leukemia: Systematic Review and Meta-Analysis.

Authors:  Xiangwen Wang; Dan Mu; Anyang Geng; Anqi Zhao; Yiyuan Song
Journal:  J Healthc Eng       Date:  2022-03-18       Impact factor: 2.682

Review 9.  Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.

Authors:  Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht
Journal:  Front Pediatr       Date:  2021-12-03       Impact factor: 3.418

10.  Growth after hematopoietic stem cell transplantation in children with acute myeloid leukemia.

Authors:  Seung Joon Chung; Seung Wan Park; Min Kyoung Kim; Min Jae Kang; Young Ah Lee; Seong Yong Lee; Choong Ho Shin; Sei Won Yang; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.